PAREXEL Strengthens Commitment To Global Biopharmaceutical Workforce With New PAREXEL Academy Programs

BOSTON, April 8, 2015 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced three new academic programs at the PAREXEL Academy. The offerings span the globe and are designed to prepare students for careers in the biopharmaceutical industry:

• Bachelor of Science Degree in Clinical Research – Offered in partnership with the Medical School Berlin, in Berlin, Germany, the degree program features courses specific to clinical research. Courses range from ethics in health and medicine to conducting clinical trials. Several courses are taught by PAREXEL experts.
• Postgraduate Certificate in Clinical Trial Management – In cooperation with Salem State University in Salem, Massachusetts, the postgraduate certificate program features a broad-based curriculum in various components of the full life cycle of drug development.
• Joint Program for Clinical Research and Clinical Trial Management – In collaboration with Kyoto Pharmaceutical University in Kyoto, Japan, the joint program provides fifth grade undergraduate students an introductory, seven-week course in clinical research and clinical trial management.

"PAREXEL is committed to developing the biopharmaceutical industry's next-generation global workforce," said Heidrun Bruchmann, Ph.D., Senior Director, PAREXEL Academy.  "Through the PAREXEL Academy, we tailor educational and degree programs with our partners to equip the future health sciences workforce with a holistic and cross-functional foundation in clinical research and clinical trial management."

For more than a decade, the PAREXEL Academy has designed and implemented a wide range of learning programs tailored to enable clinical research management practices for learners inside and outside of PAREXEL. The PAREXEL Academy has locations in the United States, Europe, and Asia.  Since inception, approximately 1,000 students have graduated from the Academy's programs, including its undergraduate Bachelor of Science program. 

Mary L. Churchill, Ph.D. Associate Provost, Innovation and Partnerships, Salem State University, commented that, "Salem State is committed to providing students with programs that are both foundational and workforce-aligned. Through our partnership with the PAREXEL Academy, we create programs to give students the specific tools needed to succeed post-graduation in biopharmaceutical research."

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 16,530 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisition of ClinIntel Limited, or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2015 as filed with the Securities and Exchange Commission on February 5, 2015, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Contacts:
Diana Martin, PAREXEL International
Tel: +1 781-434-5516
Email: [email protected]

Cristi Barnett, PAREXEL International
Tel.: +1 781-434-4019
Email: [email protected]

Matthew Briggs, PAN Communications
Tel: +1 617-502-4300
Email: [email protected]

SOURCE PAREXEL International Corporation

Related Links

http://www.parexel.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED